246 related articles for article (PubMed ID: 27956136)
1. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol
Kumaki Y; Salazar AM; Wandersee MK; Barnard DL
Antiviral Res; 2017 Mar; 139():1-12. PubMed ID: 27956136
[TBL] [Abstract][Full Text] [Related]
2. Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice.
Kumaki Y; Day CW; Bailey KW; Wandersee MK; Wong MH; Madsen JR; Madsen JS; Nelson NM; Hoopes JD; Woolcott JD; McLean TZ; Blatt LM; Salazar AM; Smee DF; Barnard DL
Antivir Chem Chemother; 2010 Mar; 20(4):169-77. PubMed ID: 20231782
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.
Wong JP; Saravolac EG; Sabuda D; Levy HB; Kende M
Antimicrob Agents Chemother; 1995 Nov; 39(11):2574-6. PubMed ID: 8585749
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin.
Kumaki Y; Wandersee MK; Smith AJ; Zhou Y; Simmons G; Nelson NM; Bailey KW; Vest ZG; Li JK; Chan PK; Smee DF; Barnard DL
Antiviral Res; 2011 Apr; 90(1):22-32. PubMed ID: 21338626
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.
Kende M; Paragas J; Salazar AM
Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774
[TBL] [Abstract][Full Text] [Related]
6. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
7. Intranasal treatment with poly(I•C) protects aged mice from lethal respiratory virus infections.
Zhao J; Wohlford-Lenane C; Zhao J; Fleming E; Lane TE; McCray PB; Perlman S
J Virol; 2012 Nov; 86(21):11416-24. PubMed ID: 22915814
[TBL] [Abstract][Full Text] [Related]
8. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
[TBL] [Abstract][Full Text] [Related]
9. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC.
Wong JP; Yang H; Nagata L; Kende M; Levy H; Schnell G; Blasetti K
Vaccine; 1999 Mar; 17(13-14):1788-95. PubMed ID: 10194841
[TBL] [Abstract][Full Text] [Related]
10. Novel antiviral therapeutics to control foot-and-mouth disease.
Dias CC; Moraes MP; Weiss M; Diaz-San Segundo F; Perez-Martin E; Salazar AM; de los Santos T; Grubman MJ
J Interferon Cytokine Res; 2012 Oct; 32(10):462-73. PubMed ID: 22924938
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
Kende M
J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
[TBL] [Abstract][Full Text] [Related]
12. Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer.
Coppenhaver DH; Singh IP; Sarzotti M; Levy HB; Baron S
Am J Trop Med Hyg; 1995 Jan; 52(1):34-40. PubMed ID: 7531956
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
[TBL] [Abstract][Full Text] [Related]
14. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model.
Kumaki Y; Ennis J; Rahbar R; Turner JD; Wandersee MK; Smith AJ; Bailey KW; Vest ZG; Madsen JR; Li JK; Barnard DL
Antiviral Res; 2011 Jan; 89(1):75-82. PubMed ID: 21093489
[TBL] [Abstract][Full Text] [Related]
15. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
16. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
Puri SK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
[TBL] [Abstract][Full Text] [Related]
17. Optimization of an immunotherapeutic protocol with poly(I,C)-LC.
Talmadge JE; Hartmann D
J Biol Response Mod; 1985 Oct; 4(5):484-9. PubMed ID: 4078594
[TBL] [Abstract][Full Text] [Related]
18. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Chan PK; Sidwell RW
Antivir Chem Chemother; 2006; 17(5):275-84. PubMed ID: 17176632
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection.
Li Y; Hu Y; Jin Y; Zhang G; Wong J; Sun LQ; Wang M
J Gene Med; 2011 Jan; 13(1):60-72. PubMed ID: 21259409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
